Relevant bibliographies by topics / Fluorouracil – Analyse

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Fluorouracil – Analyse'

Author: Grafiati
Published: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Fluorouracil – Analyse.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Fluorouracil – Analyse"

1

Kadziauskienė, Aistė, Ernesta Strelkauskaitė, Eglė Mockevičiūtė, Rimvydas Ašoklis, Eugenijus Lesinskas, and Leopold Schmetterer. "Changes in macular thickness after trabeculectomy with or without adjunctive 5-fluorouracil." Acta medica Lituanica 24, no. 2 (July 17, 2017): 93–100. http://dx.doi.org/10.6001/actamedica.v24i2.3489.

Full text
Abstract:
Conflict of interest. None of the authors have any conflict of interest to declare, financial or otherwise. No financial or other support was received for the study. Background. The aim of the study was to assess changes in macular thickness after trabeculectomy in respect to the use of 5-fluorouracil (5-FU) as well as to analyse possible associations between the postoperative changes in macular thickness and intraocular pressure (IOP). Materials and methods. The prospective observational study included 106 eyes (100 patients) with glaucoma who underwent trabeculectomy with or without 5-FU. Subsequently 5-FU needling was performed if failure of the filtrating bleb occurred. Macular thickness and the IOP were evaluated before, one week, and six months after the surgery. The mean and sectoral macular thickness was assessed using spectral domain optical coherence tomography. Results. The mean (±SD) IOP reduced from 27.71 (±6.88) mmHg at baseline to 18.3 (±8.1) mmHg one week (p
APA, Harvard, Vancouver, ISO, and other styles
2

Engelman, Dan, Michel Moreau, Antonia Lepida, Yasmine Zaouak, Marianne Paesmans, and Ahmad Awada. "Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity." ESMO Open 5, no. 3 (June 2020): e000695. http://dx.doi.org/10.1136/esmoopen-2020-000695.

Full text
Abstract:
PurposePseudocirrhosis is a radiological term used to describe rapid changes in the contour of liver invaded by metastases and treated with chemotherapy. Our primary objectives were to analyse the clinical and biological characteristics of those patients with breast cancer and to assess the prevalence of complications generally associated with decompensated cirrhosis. We have also assessed associated treatments and response.MethodsThis retrospective study included all women with metastatic breast cancer to the liver who had imaging protocols describing diffuse liver contour abnormalities during systemic treatment between 2003 and 2018 in our centre. The following were identified: neoplastic characteristics, complications presented, treatments administered and response.Results48 patients were included. There was a trend towards an increased proportion of luminal cancers (88.2%, n=30, p=0052) when compared with our hospital cancer registry. Most patients (97.9%, n=47) had a widespread liver invasion, 58.3% (n=28) had ascites on physical examination; 90% (n=18) of ascites were classified as transudate. Nearly 23% (n=11) of patients had oesophageal varices and 6.5% (n=3) had an episode of variceal rupture. At the time of the appearance of liver contour abnormalities, the most frequently used molecules were: 5-fluorouracil (22.9%; n=11) and cisplatin (18.8%; n=9). A partial response was observed in 52.1% (n=25) of patients.ConclusionThis is the largest reported series of patients with pseudocirrhosis. Many patients developed complications related to portal hypertension and liver failure, similar to those observed in decompensated cirrhosis. Luminal subtypes could be over-represented. In our series, pseudocirrhosis appears to develop at the expense of extensive liver disease burden and most often under 5-fluorouracil, or its derivatives, with or without cisplatin, possibly following a response to treatment.
APA, Harvard, Vancouver, ISO, and other styles
3

Thomas, Ritty Ann, and Vasim Ismail Patel. "A comparative analysis between intralesional 5-fluorouracil versus surgical excision with intralesional triamcinalone acetonide in keloid excision." International Journal of Otorhinolaryngology and Head and Neck Surgery 6, no. 5 (April 21, 2020): 904. http://dx.doi.org/10.18203/issn.2454-5929.ijohns20201684.

Full text
Abstract:
<p class="abstract"><strong>Background:</strong> Keloids are characterized by an uncontrolled proliferation of fibrous tissue after injury of the skin and has been treated by various modalities. Recently, newer therapeutic modalities have been studied including intralesional 5-FU, verapamil, laser therapy, cryotherapy, silicone sheet dressings, irradiation, retinoids, tacrolimus, imiquimod and combination therapy. The aim of this study is to analyse the response of intralesional 5-FU alone with that of intralesional triamcinolone acetonide with surgical excision thus to provide the best possible treatment modality to patients.</p><p class="abstract"><strong>Methods:</strong> Sixteen patients having keloid in head and neck region were taken into the study and divided into two groups after a routine blood check-up. Group A intralesional 5-FU once in three weeks for six sessions. Group B surgical excision followed by intralesional triamcinalone acetonide once weekly for six sessions. Patients were followed up for one year. </p><p class="abstract"><strong>Results:</strong> In group A, 7 patients came for review regularly. Aesthetic improvement was excellent for 6 but was considerably painful for all. In group B, 8 patients came for regular review, 6 had minimal scarring and all patients complained of mild pain post operatively.</p><p><strong>Conclusions:</strong> Intralesional 5-FU can be a very effective treatment modality for keloids, with no recurrence noted, except for its poor tolerability owing to side effects such as pain, nausea and vomiting. Classical method of surgical excision followed by intralesional steroids is better tolerated but has higher recurrence rates. </p>
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Cong, Hongpeng Liu, Bin Ma, Yongxi Song, Peng Gao, Yingying Xu, Dehao Yu, and Zhenning Wang. "The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis." Disease Markers 2017 (2017): 1–11. http://dx.doi.org/10.1155/2017/9202676.

Full text
Abstract:
The potential impact that the intratumoral expression level of dihydropyrimidine dehydrogenase (DPD) has on chemotherapy sensitivity and long-term survival for gastric cancer (GC) patients remains controversial; therefore, this study seeks to clarify this issue. Our meta-analysis was performed using Review Manager (RevMan) 5.3 software. In vitro drug sensitivity tests, correlation coefficients between sensitivity to 5-fluorouracil (5-FU), and expression levels of intratumoral DPD were used as effective indexes to analyse. Overall survival (OS) and progression-free survival (PFS) were used as endpoints for patient outcome, and hazard ratios (HRs) and 95% confidence intervals (CIs) were noted as measures of effect. There were 15 eligible studies including 1805 patients for the final analysis. The analysis revealed a statistically significant difference between the expression level of intratumoral DPD activity, DPD mRNA levels, and sensitivity to 5-FU in GC patients, with high expression levels of intratumoral DPD resulting in low sensitivity to 5-FU. However, no matter what therapeutic regimens were used, there was no significant difference for patient outcomes between high and low DPD expression groups, either in OS or in PFS. In conclusion, high levels of intratumoral DPD expression have a negative impact on sensitivity to 5-FU in GC patients, but no prognostic value for long-term survival was uncovered.
APA, Harvard, Vancouver, ISO, and other styles
5

Izyumov, Mikhail Sergeevich, Viktor Viktorovich Bulynin, Andrey Mikhailovich Bobrovskih, and Olga Gennadevna Deryaeva. "Comparative Assessment of Morphological Changes in the Pleura and Lung Tissue after Pleurodesis with Various Solutions in the Experiment." Journal of Experimental and Clinical Surgery 15, no. 2 (June 24, 2022): 147–53. http://dx.doi.org/10.18499/2070-478x-2022-15-2-147-153.

Full text
Abstract:
Introduction. Currently, spontaneous pneumothorax occurs in 6,2-7,1% of patients with nonspecific lung diseases. There has been a steady increase in prevalence of this disease. The relevance of preventing recurrence of spontaneous pneumothorax is still beyond doubt. Most authors recommend performing chemical pleurodesis when nonspecific spontaneous pneumothorax occurs, especially if it is recurrent. At the present time, the issue of choosing the optimal chemical agent for performing pleurodesis remains important.The aim of the study was to analyse the nature and severity of the inflammatory reaction from the lungs, pleura and adjacent subpleural tissues of the chest wall in experimental animals during chemical pleurodesis with 4% sodium bicarbonate, 6% hydrogen peroxide and 5-fluorouracil solutions.Materials and methods. The experiment was conducted at the experimental laboratory of Voronezh Regional Clinical Hospital № 1. The study involved 200 experimental rats (WISTAR type) with simulated spontaneous pneumothorax; after a fixed time, one of the preparations was sprayed into the pleural cavity. All animals were divided into 3 groups depending on the method of pleurodesis (5-fluorouracil solution, 4% sodium bicarbonate solution and 6% hydrogen peroxide solution) and control (0,9% sodium chloride solution). Groups of animals were withdrawn from the experiment in accordance with the rules of humane treatment of animals in 3, 5, 7, 10, 30 days with sampling of organs and tissues of the chest for histological examination to compare severity of inflammatory reactions in the pleura and adjacent areas of the lungs depending on the drug used for pleurodesis. The main criterion for assessing the comparative effectiveness of chemical agents was the morphological picture of inflammation presented by counting free cell populations (lymphocytes, macrophages, neutrophils, histiocytes) in the pleura and adjacent areas of the lung tissue of the studied animals.Quantitative results were statistically processed using parametric and nonparametric methods with STATISTICA 10. The main statistical parameters of the studied data were estimated by the methods of descriptive statistics. Comparison of the studied samples was conducted with the Kruskal-Wallis test. Differences between the compared samples were considered significant at p0,05.Results. The morphology of the inflammatory reaction in the pleura and adjacent lung tissue in all the studied groups of animals was characterized by the predominance of neutrophils over other cells in the first days of the experiment; the fact supporting acute aseptic inflammation in response to drug administration. Further, the content of lymphocytes, macrophages and their inactive forms (histiocytes) increased, and the content of neutrophils decreased, which was typical for the transition of acute inflammation to chronic. Compared dynamics in the number of analyzed immunocompetent cells evidenced that the number of lymphocytes, macrophages and histiocytes increased faster. After pleurodesis with a 6% hydrogen peroxide solution, the lowest content of immunocompetent cells in the studied tissue samples was noted if compared with the samples obtained from other groups in the same period. In all cases, pleurodesis with 6% hydrogen peroxide resulted in the minimal number of neutrophils, and the dynamics of their decrease was the most pronounced. In the control group, the number of studied cells fluctuated within the average value for this group.Conclusion. The dynamics in the number of studied cell populations in all comparison groups was assessed as common. The method of pleurodesis significantly affects the number of cellular elements involved in the inflammatory response. Clinical outcomes of pleurodesis performed with a 6% hydrogen peroxide solution are characterized by a shorter duration and severity of the inflammatory response from the pleura and adjacent parts of the chest wall, compared with 5-fluorouracil and 4% sodium bicarbonate solutions.
APA, Harvard, Vancouver, ISO, and other styles
6

Mohan, Ambikavathy, and Chandan Kumar. "Clinical profile and management of breast cancer in women in a rural based tertiary care hospital our experience." International Surgery Journal 4, no. 2 (January 25, 2017): 697. http://dx.doi.org/10.18203/2349-2902.isj20170216.

Full text
Abstract:
Background: Breast cancer is the second most common cancer among women in India and accounts for 7% of global burden of breast cancer and one-fifth of all cancers among women in India. The risk factors are related to lifestyle, early menarche, nulli parity, prolonged use of oral contraceptive pills, hormone replacement therapy, not breast‑feeding, alcohol, obesity, lack of exercise, and induced abortion. A woman who attains menopause after fifty five years of age has an increased risk of ovarian, breast, and uterine cancers. The risk is greater if a woman also began menstruating before twelve years of age. A longer exposure to estrogen increases a woman’s risk of breast cancers.Methods: This is a prospective observational study, conducted in the department of surgery, between December 2013 and June 2015(2 years). Patients diagnosed as breast carcinoma and admitted in surgical wards were included, Data pertaining to demography, clinical and pathological tumor profile, and treatment details were collected prospectively for each patient based on patient interviews and medical records. To analyse the Prevalence of breast cancer, clinical presentation, risk factors, diagnostic methods, treatment protocols, difference between pre and post‑menopausal breast cancer women regarding risk factors, assess the impact of treatment given and women’s knowledge about breast cancer.Results: A total number of 25 cases of breast carcinoma based on detailed history, clinical examination, Trucut biopsy, ultrasonography breast and axilla, ultrasound abdomen, mammogram and chest x-ray were analysed. All of them received three cycles of anterior chemotherapy consisting of 5- Fluorouracil 500 mg/m2,Adriamycin 50 mg/m2 Cyclophosphamide 80 mg/m2 (FAC regimen) administered intravenously followed by modified radical mastectomy. There were no recurrences seen on follow up till date.Conclusions: Late stage at presentation of breast cancer is a challenge to the health care providers. Cancer awareness programmes, multidisciplinary approach and evidence‑based strategies for early detection and effective management of the disease can go a long way in prevention.
APA, Harvard, Vancouver, ISO, and other styles
7

Simon, Ole, Georg Beyer, Ujjwal Mahajan, and Julia Mayerle. "Pankreaskarzinom 2018 – reif für personalisierte Therapiekonzepte?" TumorDiagnostik & Therapie 40, no. 03 (April 2019): 180–83. http://dx.doi.org/10.1055/a-0870-8867.

Full text
Abstract:
Zusammenfassung Epidemiologie Die 5-Jahres-Überlebensrate (5-JÜR) aller Pankreaskarzinompatienten liegt mit rund 6 % sehr niedrig und die potenziell kurative Operation ist nur bei 15 – 20 % der Erkrankten möglich. Durch häufigeren Einsatz und Kombination systemischer Chemotherapeutika konnte in den letzten Jahren eine verbesserte Lebenserwartung erreicht werden. Resektables Stadium Nach vollständiger operativer Resektion eines Pankreaskarzinoms trägt eine adjuvante Chemotherapie zur Verlängerung des Gesamtüberlebens bei. Mittel der Wahl sind Gemcitabin oder 5-Fluorouracil (5-FU) und Folinsäure (FS). Kürzlich konnte für die Kombination aus Gemcitabin und Capecitabin (Gem-Cap) eine signifikante Verlängerung des Gesamtüberlebens im Vergleich zur Gemcitabin-Monotherapie gezeigt werden. Für den Einsatz einer adjuvanten Radiochemotherapie gibt es derzeit keine Empfehlung. Borderline-resektables Stadium Eine neoadjuvante Therapie hat bei Pankreaskarzinomen außerhalb klinischer Studien keinen Stellenwert. Eine Ausnahme stellen borderline-resektable Pankreaskarzinome dar. Fortgeschrittenes Stadium (M1) Patienten mit fortgeschrittenem oder metastasiertem Pankreaskarzinom profitieren von einer Chemotherapie. Für Patienten mit gutem ECOG-Status konnte kürzlich in 2 Phase-III-Studien eine signifikante Lebenszeitverlängerung durch die Kombination aus Gemcitabin plus nab-Paclitaxel (Gem-Nab) sowie durch das Kombinationsschema aus Folinsäure, 5-FU, Irinotecan und Oxaliplatin (FOLFIRINOX) gezeigt werden. In der Zweitlinie steht nanoliposomales Irinotecan oder Oxaliplatin kombiniert mit 5FU/FS (OFF) zur Verfügung. Personalisierte Therapien Die molekulare Charakterisierung des Pankreaskarzinoms hat Fortschritte gemacht und bietet schon heute Ansätze zur personalisierten Medizin. Bei gutem ECOG-Status sollte vor Zweitlinientherapie eine MSI-H/dMMR-Analyse erfolgen, um den möglichen Einsatz einer Checkpoint-Inhibitor-Therapie zu evaluieren. Bei BRCA-Mutationen kann die Gabe von PARP-Inhibitoren vielversprechend sein.
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Xiaorong, Weibing Leng, YuWen Zhou, Yongyang Yu, Wenjian Meng, Peng Cao, Ziqiang Wang, and Meng Qiu. "Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial." BMJ Open 13, no. 1 (January 2023): e062659. http://dx.doi.org/10.1136/bmjopen-2022-062659.

Full text
Abstract:
IntroductionNeoadjuvant chemotherapy (NAC) has been demonstrated effective in several tumours, but its benefit has not yet been elucidated in colorectal cancer, especially locally advanced colorectal cancer (LACRC).Methods and analysisThis is a single-arm, open-label, prospective phase II exploratory clinical trial. Patients with LACRC will receive four cycles of NAC with 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI), followed by operation and then adjuvant chemotherapy with capecitabine and oxaliplatin for two to five cycles or single-agent capecitabine for five cycles, or observation. The primary endpoint is the rate of tumour regression grade (TRG) 0–2 in the resected tumour tissue, which is evaluated by experienced pathologists according to the Ryan R TRG grading system. Secondary endpoints include objective response rate, pathologic complete response, microscopically complete resection rate, progression-free survival, distant metastasis-free survival, overall survival, toxicity and compliance to study treatment, molecular markers, quality of life to study treatment and the number of patients with 30-day postoperative mortality. The objective of this study is to analyse the efficacy and safety of FOLFOXIRI as the NAC regimen in patients with LACRC and to identify a promising treatment strategy in this setting.Ethics and disseminationWritten informed consent will be required from and provided by all patients enrolled. The study protocol has been approved by the independent ethics committee of West China Hospital, Sichuan University (approval number: 2021403). This study will demonstrate the potential benefit of NAC with the FOLFOXIRI regimen. Results will be shared with policymakers and the academic community to promote the clinical management of colon cancer.Trial registration numberNCT05018182.
APA, Harvard, Vancouver, ISO, and other styles
9

Raj, Ben, and Madhan Shankar S. R. "Analysis Of Anticancer Activity And Its Molecular Interaction Mechanism Of Withanone, An Active Ingredient Of Withania Somnifera Using Molecular Docking." International Journal of pharma and Bio Sciences 11, no. 6 (November 30, 2021): 35–41. http://dx.doi.org/10.22376/ijpbs/lpr.2021.11.6.l35-41.

Full text
Abstract:
Withania somnifera is an annual evergreen shrub from the Solanaceae family, commonly known as Indian ginseng or Ashwagandha. The plant is mainly found in Asia and Africa regions. In the traditional Indian medicinal system ayurveda, Withania somnifera is used as a rejuvenator and sold in many countries as a dietary supplement. Withanolides are the major phytochemical constituent group found in the Withania somnifera, among which withaferin A and withanone, are considered to be major withanolides, which believed to be involved in majority of biological activity of Withania somnifera. Various studies including both in vitro and in vivo have reported regarding the anticancer potential of Withania somnifera. Along with the anticancer activity of W.somnifera, the anticancer efficacy of one of its major ingredients Withaferin A is also studied previously. This study aimed to analyse the anticancer potential of another major Withanolide present in W. Somnifera, Withanone. The study used Molecular Docking method to find the molecular binding affinity of Withanone towards various cancer proteins. The four major cancer proteins were B-cell lymphoma- extra large (Bcl-xL), Cellular FLICE (c-FLIP), Glutathione Reductase (GR) and Glutathione S- Transferases (GST). The protein structure obtained from the protein data bank and the structure of the molecule obtained from pubchem were modified and prepared for Docking studies with the help of MGL Tools. The protein ligand interaction study was conducted using the software, Autodock vina. The already known anticancer standard, 5-FluoroUracil is used as standard for comparison. Output obtained from the study is visualised using molecular visualiser tool, Pymol. Like the Withaferin A, Withanone also exhibited promising anticancer activity while studied using molecular docking methods.
APA, Harvard, Vancouver, ISO, and other styles
10

Ortega-García, María Belén, Alberto Mesa, Elisa L. J. Moya, Beatriz Rueda, Gabriel Lopez-Ordoño, Javier Ángel García, Verónica Conde, et al. "Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy." Cancers 12, no. 2 (February 7, 2020): 379. http://dx.doi.org/10.3390/cancers12020379.

Full text
Abstract:
Colorectal cancer treatment has advanced over the past decade. The drug 5-fluorouracil is still used with a wide percentage of patients who do not respond. Therefore, a challenge is the identification of predictive biomarkers. The protein kinase R (PKR also called EIF2AK2) and its regulator, the non-coding pre-mir-nc886, have multiple effects on cells in response to numerous types of stress, including chemotherapy. In this work, we performed an ambispective study with 197 metastatic colon cancer patients with unresectable metastases to determine the relative expression levels of both nc886 and PKR by qPCR, as well as the location of PKR by immunohistochemistry in tumour samples and healthy tissues (plasma and colon epithelium). As primary end point, the expression levels were related to the objective response to first-line chemotherapy following the response evaluation criteria in solid tumours (RECIST) and, as the second end point, with survival at 18 and 36 months. Hierarchical agglomerative clustering was performed to accommodate the heterogeneity and complexity of oncological patients’ data. High expression levels of nc886 were related to the response to treatment and allowed to identify clusters of patients. Although the PKR mRNA expression was not associated with chemotherapy response, the absence of PKR location in the nucleolus was correlated with first-line chemotherapy response. Moreover, a relationship between survival and the expression of both PKR and nc886 in healthy tissues was found. Therefore, this work evaluated the best way to analyse the potential biomarkers PKR and nc886 in order to establish clusters of patients depending on the cancer outcomes using algorithms for complex and heterogeneous data.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Fluorouracil – Analyse"

1

Švobaitė, Rūta. "Phénotypage et génotypage de l'activité de la dihydropyrimidine déshydrogénase chez des patients atteints de tumeurs solides avec métastases : Pharmacocinétique de la capécitabine." Montpellier 1, 2009. http://www.theses.fr/2009MON13513.

Full text
Abstract:
Dans la première partie de cette thèse, les données bibliographiques concernant le cancer colorectal et ses traitements ainsi que les propriétés physicochimiques, la pharmacologie et la pharmacocinétique du 5-fluorouracile et de sa prodrogue capécitabine sont présentés. La mise au point et la validation de deux méthodes de dosage sont développées dans la deuxième partie. La première méthode concerne le dosage de l���uracile (U) et de son métabolite le dihydrouracile (UH2); la deuxième méthode concerne le dosage de la capécitabine et de quatre de ses métabolites. Ces méthodes ont été validées selon les critères recommandés par la FDA et l’Union Européenne. La démarche qualité adoptée ici est fondamentale pour la validation des résultats obtenus par la suite. Dans la troisième partie, nous présentons la méthodologie et les résultats d’une étude réalisée pour évaluer le génotype et le phénotype de la dihydropyrimidine déshydrogénase chez des patients atteints de tumeurs solides avec métastases. La plupart de ces patients souffrait de cancer colorectal. Le phénotype a été estimé à partir du rapport UH2/U. Pour le génotype, nous avons recherché les 4 mutations suivantes: 85T>C localisée sur l’exon 2; 1627A>G localisée sur l’exon 13; IVS14+1G>A localisée sur l’intron 14; et 2846A>T localisée sur l’exon 22. La dernière partie rapporte les résultats d’une étude pharmacocinétique réalisée chez des patients recevant la capécitabine par voie orale deux fois par jour. Dans ce travail, les paramètres pharmacocinétiques de la capécitabine et ceux de ses métabolites sont présentés et discutés. Nous terminons cette thèse par une discussion conclusion et nous donnons quelques perspectives.
APA, Harvard, Vancouver, ISO, and other styles
2

Ávila, Paulo Henrique Marcelino de. "Ação da formulação mucoadesiva contendo Bidens pilosa L (Asteraceae) sobre a mucosite intestinal induzida por 5- fluorouracil em camundongos." Universidade Federal de Goiás, 2013. http://repositorio.bc.ufg.br/tede/handle/tede/5059.

Full text
Abstract:
Submitted by Cláudia Bueno (claudiamoura18@gmail.com) on 2016-01-06T17:01:03Z No. of bitstreams: 2 Dissertação - Paulo Henrique Marcelino de Ávila - 2013.pdf: 2780705 bytes, checksum: b65c3f939421d3e023fe329d0423cacf (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-01-07T08:24:25Z (GMT) No. of bitstreams: 2 Dissertação - Paulo Henrique Marcelino de Ávila - 2013.pdf: 2780705 bytes, checksum: b65c3f939421d3e023fe329d0423cacf (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Made available in DSpace on 2016-01-07T08:24:25Z (GMT). No. of bitstreams: 2 Dissertação - Paulo Henrique Marcelino de Ávila - 2013.pdf: 2780705 bytes, checksum: b65c3f939421d3e023fe329d0423cacf (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2013-08-27
Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq
The gastrointestinal mucositis is a side effect caused by anti-cancer chemotherapy. Among the drugs used in antineoplastic therapy 5-fluorouracil (5-FU) deserves special attention since the incidence of intestinal mucositis is 80% on treated patients. Despite many studies on intestinal mucositis induced by chemotherapy has been carried out, there aren't effective methods for treating intestinal mucositis, only palliative measures. Moreover, several studies reported anti-inflammatory and immunomodulatory activity of Bidens Pilosa L (BPL). Objective: To investigate the action of BPL in intestinal mucositis induced by 5-FU in mice. Methods: in this study, male Swiss mice were given doses of BPL (75, 100 and 125 mg / kg) and vehicle formulation administered orally (gavage) for 6 days, while doses of 5-FU (200 mg / kg ) were administered (intraperitoneal) from the 4th to 6th day (except in the groups treated with vehicle and formulation of BPL). On day 7, the mice were euthanized and the portion instestinal of each animal was extracted to perform the histomorformetria; expression analysis of Bax, Bcl2 p53 and Ki67 by immunohistochemistry analysis of the inflammatory process through the activity of the enzyme myeloperoxidase (MPO), and evaluation lipid peroxidation by determination of levels malondialdehyde (MDA). It is importantly to note that only the dose of BPL 100 mg/kg which showed better results in the analysis weight and histomorphometric , was chosen to make the immunohistochemistry, MDA and MPO assays.Results:The doses of BPL 75, 100 and 125 mg / kg showed reduce damage triggered by 5-FU in the intestinal mucositis. However the dose of 100 mg / kg was presented the best results in terms of reduction in body mass, as well as morphometric and histological changes induced by 5-FU. Furthermore it was found that treatment with only 3 doses of BPL (75, 100 and 125 mg / kg) caused no toxicological change. It was also found that the expression rate between Bax and Bcl2 were lower in the 100 mg / kg of BPL. Moreover, the dose of 100 mg / kg of BPL showed proliferative effect with increased expression of Ki67 and reduction of inflammatory infiltrate and lipid peroxidation intestinal tissue Conclusion: The results demonstrated that BPL reduced overall damage by 5-FU in intestinal mucositis induced in mice.
A mucosite intestinal (MI) é um efeito colateral causada pela quimioterapia anti-câncer. Dentre os medicamentos utilizados na terapia antineoplásica, o 5 fluorouracil (5-FU) se destaca por causar uma incidência de mucosite intestinal de 80% nos pacientes tratados. Apesar de muitos estudos sobre a mucosite intestinal induzida por quimioterapia terem sido realizados, ainda não existem métodos eficazes para o seu tratamento, havendo apenas medidas paliativas. Nesse contexto, o uso de plantas medicinais como a Bidens Pilosa L (Asteraceae) (BPL) se torna uma alternativa promissora em virtude da sua atividade anti-inflamatória e imunomoduladora. Objetivo: Investigar a ação da BPL na mucosite intestinal induzida por 5-FU em camundongos. Métodos: Neste estudo, camundongos machos Swiss receberam as doses da formulação de BPL (75, 100 ou 125 mg/kg) ou veículo da formulação de BPL que foram administradas por via oral (gavagem) durante 6 dias, enquanto que as doses de 5-FU (200 mg/kg) foram administradas do 4º ao 6º dia, (exceto nos grupos tratados apenas com formulação de BPL e veículo).No 7º dia, os camundongos foram eutanasiados e a porção intestinal de cada animal foi extraída para realização da histomorformetria; análise da expressão de Bax, Bcl2 p53 e Ki67 por imunohistoquímica; análise do processo inflamatório através da atividade da enzima mieloperoxidase (MPO); e avaliação da peroxidação lipídica pela determinação dos níves de malondialdeído (MDA). É importante destacar que apenas a dose de BPL de 100 mg/kg foi a que apresentou melhores resultados na análise ponderal de peso e histomorfométrica, foi escolhida para fazer os ensaio de imunohistoquímica, MDA e MPO. Resultados: As doses de BPL de 75, 100 e 125 mg/kg mostraram reduzir o dano desencadeado pelo 5-FU na mucosite intestinal. Entretanto a dose de 100 mg/kg foi a que apresentou melhores resultados quanto a redução de massa corporal, assim como as alterações morfométricas e histológicas provocadas pelo 5-FU. Além disso foi verificado que o tratamento apenas com as 3 doses de BPL (75, 100 e 125 mg/kg) não provocou alterações toxicológicas. Também foi constatado que a taxa de expressão entre Bax e Bcl2 foi menor na dose de 100 mg/kg. Ademais, a dose de 100 mg/kg de BPL apresentou efeito proliferativo com aumento da expressão de Ki67, e redução de infiltrado inflamatório e peroxidação lipídica do tecido intestinal. Conclusão: Os resultados demonstraram que a BPL reduziu de modo geral os danos provocados pelo 5-FU na mucosite intestinal induzida em camundongos.
APA, Harvard, Vancouver, ISO, and other styles
3

Oliveira, Suilane Coelho Ribeiro. "Estudo de fase II de substituição do 5-FU por capecitabina no esquema de quimio-radioterapia em pacientes com carcinoma de células escamosas do canal anal." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-01042015-105449/.

Full text
Abstract:
Introdução: O carcinoma de células escamosas (CEC) do canal anal é uma neoplasia pouco frequente, correspondendo a 1-5% dos tumores intestinais. Entretanto, o risco de CEC do canal anal vem crescendo. O tratamento padrão do CEC de canal anal nos estádios II-III consiste em 5-fluorouracil infusional associado a mitomicina-C e radioterapia, desde 1974. Estudos clínicos com o objetivo de identificar novos esquemas terapêuticos mais convenientes para câncer do canal anal devem continuar. Métodos: Pacientes com CEC de canal anal T2-4N0M0 ou T (qualquer) N1-3M0, com bom performance clínico, função renal e hematológica normais foram tratados com capecitabina 825 mg/m2 12/12 horas durante a radioterapia associada a dose única de mitomicina-C 15 mg/m2 no Dia 1. O objetivo primário do estudo foi determinar a taxa de controle local em 6 meses da associação de capecitabina, mitomicina-C e radioterapia em pacientes com câncer do canal anal. Os objetivos secundários foram determinar a taxa de toxicidade aguda graus 3-4, conforme os critérios da CTCaev4.0, taxa de resposta completa 6 semanas após término da quimio-radioterapia, sobrevida global e livre de progressão e taxa de colostomia em 1 ano. O tamanho da amostra foi calculado usando a ferramenta \"estágio único de Fleming\". Considerando 85% de eventos esperados (taxa de controle local em 6 meses), 1 desvio padrão e 5% de erro alfa, o tamanho ideal da amostra foi de 51 pacientes. Resultados: De novembro/2010 a fevereiro/2014, 51 pacientes foram incluídos, sendo avaliados 43 pacientes. Dezessete pacientes (39,5%) tinham estádio II, 11 (25,6%) estádio IIIA e 15 (34,9%) estádio IIIB. O seguimento mediano foi de 23,1 meses. Entre os pacientes que foram avaliados em 6 meses, 3 (7%) apresentaram resposta clínica parcial, 37 (86%) tiveram resposta clínica completa e 3 (7%) apresentaram progressão de doença. O controle loco-regional em 6 meses foi de 86%. Em relação às toxicidades graus 3-4, observaram-se diarreia grau 3, em 4,6% dos pacientes, radiodermite grau 3, em 23,2%, vômitos grau 3, em 2,3%, plaquetopenia graus 3-4, em 6,9%, leucopenia grau 3, em 6,9%, e linfopenia grau 3, em 11,6%. Um paciente HIV positivo (2,3%) apresentou choque séptico grau 4, pneumonia grau 4, meningoencefalite herpética grau 4 e síndrome de ativação macrofágica grau 4. A taxa de colostomia foi de 18,6%. Conclusão: Capecitabina e mitomicina-C são um tratamento bem tolerado em pacientes com carcinoma de canal anal, com controle loco-regional em 6 meses em 86% dos pacientes. Palavras-chave: carcinoma de células escamosas, câncer anal, capecitabina, radioterapia, mitomicina-c
Background: Squamous cell carcinoma (SCC) of the anal canal is an uncommon malignancy accounting for 1-5% of intestinal tumors; however, its incidence has been increasing. Treatment for stage II and III anal canal SCC is infusional 5-fluorouracil associated with mitomycin and radiotherapy, since 1974. More convenient treatments for patients are needed. Methods: Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status, normal blood, and renal function were treated with capecitabine 825 mg/m2 bid during radiotherapy associated with a single dose of mitomycin 15 mg/m2 on day 1. Primary objective was local control rate at 6 months determined by clinical examination and radiological assessment. Sample size was calculated using Fleming single stage design. Results: From november/2010 to february/2014 51 patients were initially included, however 43 patients were assessed. Seventeen patients (39.5%) were stage II, 11 patients (25.6%) stage IIIA, and 15 patients (34.9%) stage IIIB. Four patients (9.3%) were HIV-positive, while 39 (90.7%) were HIV-negative. Median follow-up was 23.1 months. Among patients who finished the treatment and were reevaluated at 6 months 3 patients (7%) presented partial response, 37 patients (86%) had complete response, and 3 patients developed progression of the disease (7%). Regarding grade 3-4 toxicities, 10 patients (23.2%) had grade 3 radiodermitis, 3 patients (6.9%) had grade 3-4 thrombocytopenia, 5 (11.6%) had grade 3 lymphopenia, 1 patient (2.3%) had grade 3 vomiting, 2 patients (4.6%) had grade 3 diarrhea and 3 patients (6.9%) had grade 3 leukopenia. One HIV+ patient had septic shock, pneumonia, herpetic encephalitis and macrophage activation syndrome. Colostomy rate was 18.6%. Conclusions: Capecitabine and mitomycin with radiotherapy seem to be a safe treatment for SCC of the anal cancer, with a complete response rate in 6 months of 86%
APA, Harvard, Vancouver, ISO, and other styles
4

NOBILI, STEFANIA. "Analisi dell'espressione di geni coinvolti nella resistenza al 5-fluorouracile nel carcinoma colorettale." Doctoral thesis, 2002. http://hdl.handle.net/2158/779872.

Full text
Abstract:
5-FU-based chemotherapy (CT)is widely used in CC treatment. However, many patients (pts) still fail on these regimens due to natural or acquired tumor resistance mainly caused by increased expression of the target enzyme, thymidylate synthase (TS). In addition, a decreased activity of the folypolyglutamate synthetase (FPGS) enzyme has been associated with 5-FU resistance presumable due to the resulting depletion of folate polyglutamates, destabilizing the inhibitory TS-fluorodeoxyurilydate-folate coenzyme ternary complex. In tumor samples from 31CC pts, we measured TS and FPGS expression to establish their predictive role in prognosis for 5-FU based CT, by analizing TS and FGPS mRNA levels by RT-PCR and TS protein by immunohistochemistry. The median TS/beta-actin ratio was 41.36x10-3 (range 2,49x10-3-294,54x10-3). The TS immunostaining intensity was absent or weak in 54,8% and medium or strong in 45,2% samples. A statistically significant correlation was observed between TS mRNA and protein levels (p=0,0018). Overall median survival (OS) was significantly longer for pts with TS mRNA levels lower than the median value compared with those with higher levels (p=0.0103). Also the OS of pts with completely resected tumors (n=26) was longer for those with low TS expression compared with those with high TS expression (p=0.0092), as was disease-free survuval (DFS) (P=0.0923). Analysis of TS protein expression gave a similar correlation, although significnat only for OS of pts with completely resected tumors (p==.0041). DFS and OS data in the same pts demonstrated a significant difference between CT treated pts and surgical controls in pts with high Ts mRNA expression (p=0.0012 and 0.0006, respectively) but not in those with low TS expression. In pts undergoing surgery alone, high TS levels were unfavourable prognostic factor. Our data confirm the prognostic role of TS expression, as determined by both methods, for 5-FU based adjuvant CT. No correlation has been found between FPGS gene expression and usrvival of CC pts. The large scale evaluation of these and other molecular determinants of sensitivity may help tailor CT for CC pts and thus obtain improved efficacy.
APA, Harvard, Vancouver, ISO, and other styles
5

Bendová, Petra. "Stanovování metylací v promotorových oblastech genů řídících metabolismus 5 - fluorouracilu." Master's thesis, 2015. http://www.nusl.cz/ntk/nusl-353840.

Full text
Abstract:
Several malignant diseases, such as colorectal, pancreatic, breast or ovarial cancers, are primarily treated with cytostatics 5-fluorouracil (5-FU). 5-FU undergoes biotransformation in human body and arising metabolites induce the damage and subsequent apoptosis in the target cells. The main aim of this diploma Thesis was the determination of methylation in promoter regions of 14 candidate genes participating on 5-FU biotransformation: TK1, PPAT, RRM1, RRM2, UCK2, UCK1, UMPS, TYMP, UPP1, UPP 2 SLC29A1, UPB1, DPYS and DPYD. We hypothesize that the methylation in promoter regions regulates mRNA transcription of the above candidate genes. We have conducted appropriate analyses in 128 colorectal cancer patients, for whom both tumor and nonmalignant adjacent tissues were available. Sample processing and analysis involved DNA isolation, bisulfite conversion of unmethylated cytosines to corresponding uracils, methylation-specific analysis of melting curves with high resolution for theproper methylation analysis and gel electrophoresis to separate PCR products. For the majority of the studied genes (TK1, PPAT, RRM1, RRM2, UCK2, UCK1, UMPS, TYMP, UPP1, SLC29A1 and DPYD) we did not detect any aberrant methylation in promoter regions. In genes DPYS, UPB1 and UPP2 we recorded various degree of promoter...
APA, Harvard, Vancouver, ISO, and other styles
6

Anderson, Nicole Marie. "Generation of Mouse Models of Human Hematopoietic Disease and their Use to Analyze Hematopoietic Development and Function." Thesis, 2012. http://hdl.handle.net/1807/33872.

Full text
Abstract:
Hematopoiesis is an intricately regulated homeostatic process that maintains all of the differentiated blood cell lineages. N-ethyl-N-nitrosurea (ENU) is a powerful mutagen that induces point mutations randomly in the genome. ENU was used in a dominant forward genetic screen to identify novel mutations in regulators of hematopoiesis and to create new mouse models of hematopoietic disease. The objectives of this thesis were to characterize two mutants that originated from the dominant screen (7192 and 7238) and to develop a pharmacologically sensitized screen that would detect a unique set of mutations undetectable in the dominant screen. The 7192 mutant from the ENU dominant screen presented with elevated microcytic red blood cells (RBC) and increased polychromasia. The causative mutation was identified as a nonsense mutation in Ank1 (Q895X) that coded for a truncated ANK1 protein. Ank17192 is a novel mouse model of hereditary spherocytosis (HS), a human disease that results from increased RBC fragility. We have demonstrated that Ank17192/+ mice model a mild HS and Ank17192/7192 mice model severe HS. The 7238 mutant from the dominant ENU screen was macrothrombocytic and carried a missense mutation in Myh9 (Q1443L). The Myh97238/7238 mice are viable and have a more severe phenotype of macrothrombocytopenia. Myh97238 is the first mouse model for Myh9 related disorders that accurately models the genetic origins and the systemic manifestations of the disorder. A pharmacologically sensitized screen using chemotherapeutic drugs was designed to induce stress hematopoiesis to detect mutations that alter cell cycle of hematopoietic progenitors or stress hematopoiesis. Analysis of both peripheral blood and progenitor recovery kinetics, determined that 5-fluorouracil (5FU) and phenylhydrazine were good candidates for a pharmacologically sensitized screen. 5FU was successfully incorporated into an ENU dominant screen, and 13 platelet recovery outliers were detected. From these outliers, three mutant lines were successfully established.
APA, Harvard, Vancouver, ISO, and other styles
7

LABBOZZETTA, Manuela. "Analisi dei polimorfismi dei geni codificanti per l’enzima UDP-glucuronosiltrasferasi (UGT) e per l’enzima diidropirimidina deidrogenasi (DPD), correlati a maggiore tossicità in seguito a trattamento, rispettivamente, con Irinotecano e con 5-Fluorouracile in soggetti con tumore colon rettale (CRC)." Doctoral thesis, 2012. http://hdl.handle.net/10447/94713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

LABBOZZETTA, Manuela. "ANALISI DEI POLIMORFISMI DEI GENI CODIFICANTI PER L'ENZIMA UDP-GLUCURONILTRANSFERASI (UGT) E PER L'ENZIMA DIIDROPIRIMIDINA DEIDROGENASI (DPD), CORRELATI A MAGGIORE TOSSICITA' IN SEGUITO A TRATTAMENTO, RISPETTIVAMENTE, CON IRINOTECANO E CON 5-FLUOROURACILE IN SOGGETTI CON TUMORE COLON RETTALE (CRC)." Doctoral thesis, 2012. http://hdl.handle.net/10447/105211.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Fluorouracil – Analyse"

1

Grant, Warren, and Martin Scott-Brown. Principles of oncogenesis. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0322.

Full text
Abstract:
It is obvious that the process of developing cancer—oncogenesis—is a multistep process. We know that smoking, obesity, and a family history are strong independent predictors of developing malignancy; yet, in clinics, we often see that some heavy smokers live into their nineties and that some people with close relatives affected by cancer spend many years worrying about a disease that, in the end, they never contract. For many centuries scientists have struggled to understand the process that make cancer cells different from normal cells. There were those in ancient times who believed that tumours were attributable to acts of the gods. Hippocrates suggested that cancer resulted from an imbalance between the black humour that came from the spleen, and the other three humours: blood, phlegm, and bile. It is only in the last 100 years that biologists have been able to characterize some of the pathways that lead to the uncontrolled replication seen in cancer, and subsequently examine exactly how these pathways evolve. The rampant nature by which cancer invades local and distant tissues, as well its apparent ability to spread between related individuals led some, such as Peyton Rous in 1910, to suggest that cancer was an infectious condition. He was awarded a Nobel Prize in 1966 for the 50 years of work into investigating a link between sarcoma in chickens and a retrovirus that became known as Rous sarcoma virus. He had shown how retroviruses are able to integrate sequences of DNA coding for errors in cellular replication control (oncogenes) by introducing into the human cell viral RNA together with a reverse transcriptase. Viruses are now implicated in many cancers, and in countries where viruses such as HIV and EBV are endemic, the high incidence of malignancies such as Kaposi’s sarcoma and Burkitt’s lymphoma is likely to be directly related. There are several families of viruses associated with cancer, broadly classed into DNA viruses, which mutate human genes using their own DNA, and retroviruses, like Rous sarcoma virus, which insert viral RNA into the cell, where it is then transcribed into genes. This link with viruses has not only led to an understanding that cancer originates from genetic mutations, but has also become a key focus in the design of new anticancer therapies. Traditional chemotherapies either alter DNA structure (as with cisplatin) or inhibit production of its component parts (as with 5-fluorouracil.) These broad-spectrum agents have many and varied side effects, largely due to their non-specific activity on replicating DNA throughout the body, not just in tumour cells. New vaccine therapies utilizing gene-coding viruses aim to restore deficient biological pathways or inhibit mutated ones specific to tumour cells. The hope is that these gene therapies will be effective and easily tolerated by patients, but development is currently progressing with caution. In a trial in France of ten children suffering from X-linked severe combined immunodeficiency and who were injected with a vector that coded for the gene product they lacked, two of the children subsequently died from leukaemia. Further analysis confirmed that the DNA from the viral vector had become integrated into an existing, but normally inactive, proto-oncogene, LM02, triggering its conversion into an active oncogene, and the development of life-threatening malignancy. To understand how a tiny change in genetic structure could lead to such tragic consequences, we need to understand the molecular biology of the cell and, in particular, to pay attention to the pathways of growth regulation that are necessary in all mammalian cell populations. Errors in six key regulatory pathways are known as the ‘hallmarks of cancer’ and will be discussed in the rest of this chapter.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Fluorouracil – Analyse"

1

Staib, L., K. H. Link, W. D. Harzer, A. Käsbohrer, V. Liebig, and H. G. Berger. "Adjuvante Therapie des Kolonkarzinoms mit 5-FU/Folinsäure/Levamisol: Überlegenheit in der Kosten-Nutzen Analyse der Multicenterstudie FOGT-1 / Adjuvant Chemotherapy in Colon Cancer with 5-Fluorouracil, Folinic Acid and Levamisole: Superiority in Cost-Efficacy Analysis of the FOGT-1 Multicenter Trial." In Deutsche Gesellschaft für Chirurgie, 847. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56458-1_301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Richards, Evelleen. "Comparative Analysis of the Controversy: Vitamin C, 5-Fluorouracil and Interferon." In Vitamin C and Cancer: Medicine or Politics?, 192–215. London: Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-09606-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tanaka, Tomoaki. "Quantitative Analysis of the Enzymes Associated with 5-Fluorouracil Metabolism in Prostate Cancer Biopsies." In Methods in Molecular Biology, 301–5. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-163-5_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fouad, Damiri, Yahya Bachra, Grouli Ayoub, Amine Ouaket, Ahmed Bennamara, Noureddine Knouzi, and Mohammed Berrada. "A Novel Drug Delivery System Based on Nanoparticles of Magnetite Fe3O4 Embedded in an Auto Cross-Linked Chitosan." In Chitin and Chitosan - Physicochemical Properties and Industrial Applications [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94873.

Full text
Abstract:
Recently, chitosan (CS) was given much attention as a functional biopolymer for designing various hydrogels for industrial, environmental and biomedical applications, but their biomedical use is limited due to the toxicity of the crosslinker agents. To overcome this inconvenience, we developed an auto cross-linked material based on a chitosan backbone that carries an amino and aldehyde moieties. This new drug delivery system (DDS) was designed by using oxidized chitosan (OCS) that crosslinks chitosan (CS). In the first part, a simple, rapid, low-cost and eco-friendly green method was introduced to synthesize magnetite nanoparticles (Fe3O4-NPs) successfully. These nanoparticles Fe3O4 have received a great deal of attention in the biomedical field. Especially in a targeted drug delivery system, drug-loaded Fe3O4-NPs can accumulate at the tumor site by the aid of an external magnetic field and increase the effectiveness of drug release to the tumor site. In the second part, we have incorporated the Fe3O4-NPs into chitosan/oxidized chitosan solution because of their unique magnetic properties, outstanding magnetism, biocompatibility, lower toxicity, biodegradability, and other features. Three drugs (5-Fluorouracil (5-FU), Caffeine and Ascorbic acid)) were embedded into the magnetite solution that became quickly a hydrogel. The successful fabrication of the hydrogels and ferrogels was confirmed by (FT-IR), (TGA), (SEM), (VSM) analysis at room temperature. Finally, results showed that our hydrogels and ferrogels may be technologically used as devices for drug delivery in a controllable manner.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Fluorouracil – Analyse"

1

Cao, Yuqi, Zhangwei Huang, Jiani Chen, Pingjie Huang, Weiting Ge, Dibo Hou, and Guangxin Zhang. "Analysis and Characterization of 5-Fluorouracil based on Terahertz Spectroscopy." In Clinical and Translational Biophotonics. Washington, D.C.: OSA, 2020. http://dx.doi.org/10.1364/translational.2020.jtu3a.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gift, Alan D., Chetan S. Shende, Frank E. Inscore, and Stuart Farquharson. "Analysis of chemotherapy drug 5-fluorouracil and its metabolites by surface-enhanced Raman spectroscopy." In Optics East, edited by Brian M. Cullum. SPIE, 2004. http://dx.doi.org/10.1117/12.579353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shrestha, Shikshya, Steve Offer, and Robert B. Diasio. "Abstract 5487: Functional analysis of rare dihydropyrimidine dehydrogenase variants relevant to 5-fluorouracil toxicity." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5487.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ma, Chenhui, Alexandru Almasan, and Evren Gurkan-Cavusoglu. "Abstract 225: Computational analysis of 5-fluorouracil antitumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Smid, Kees, Erik Meijer, Thang V. Pham, Inge de Reus, Sander R. Piersma, Godefridus J. Peters, and Connie R. Jimenez. "Abstract 572: Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Quaglia, Alberto, Nikhil Aggarwa, Mark McPhail, and Kevin Monahan. "PWE-053 Meta-analysis of tumour microsatellite-instability, as a predictor of response to fluorouracil-based adjuvant chemotherapy for colon cancer." In British Society of Gastroenterology Annual Meeting, 17–20 June 2019, Abstracts. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-bsgabstracts.377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Živković Radojević, Marija, Neda Milosavljević, Slađana Aćimović Talijan, Tatjana B. Miladinović, Aleksandar Miladinović, and Miloš Grujić. "Challenges in radiotherapy planning in patients with synchronous rectal and prostate cancer and hip prosthesis." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.209zr.

Full text
Abstract:
Background. Prostate and rectal carcinomas, although among the most common malignancies in males, rarely exhibit synchronous diagnosis and treatment of both malignancies. This paper presents a case of a patient with synchronous prostate and rectal carcinoma and an artificial right hip, which complicates the creation of a radiotherapy plan. Case Report. A 76-year-old male was diagnosed with synchronous mucinous infiltrating adenocarcinoma of the rectum (T3N0M0) and adenocarcinoma of the prostate (T3aN0M0), confirmed by immunohistochemistry. He had a history of testicular carcinoma previously treated with orchiectomy, chemotherapy, and radiotherapy. The treatment approach involved neoadjuvant chemotherapy with 5-fluorouracil and leucovorin, following the protocol for rectal carcinoma, and concurrent radiotherapy for both rectal and prostate carcinoma. The presence of an artificial metal right hip prosthesis made the creation of the radiotherapy plan more challenging. The plan was developed by defining four target volumes and delineating artifacts in the soft tissue and bony structures. It was designed to deliver the prescribed dose using 6 MV photon energy during 25 radiotherapy sessions, applying a simultaneous integrated boost. The best dose delivery was achieved with the VMAT plan, and the analysis of dose-volume histograms (DVH) indicated satisfactory contributions to organs at risk. Conclusion. Individualized approaches in treating patients are particularly important in cases of synchronous tumors. As oncology patients tend to have longer overall survival, special attention must be given to the patient’s quality of life, necessitating organ sparing during radiotherapy treatment. The complexity of treatment planning due to the presence of comorbidities and metal implants is overcome through excellent collaboration between radiation oncologists and medical physicists.
APA, Harvard, Vancouver, ISO, and other styles
8

Kobunai, Takashi, Ayako Nakamura, Mamoru Nukatsuka, Kazuhiko Hayashi, and Teiji Takechi. "Abstract 991: Integrated analysis of gene expression, DNA copy number, and CpG island methylation of 5-fluorouracil-resistant human gastric cancer cell lines." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yip, Adrian Y. S., Wings T. Loo, and Louis W. C. Chow. "Abstract 2686: Analysis of cardiac markers on patients receiving 5-fluorouracil, epirubicin, cyclophosphamide with concurrent celecoxib (FEC-C) neoadjuvant therapy for locally advanced breast cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2686.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Aljohani, Hanadi G., Gehan A. Hegazy, Ali M. El-Halawany, Aliaa A. Alamoudi, Ghada M. A. Agabnoor, and Ahmed M. Al-Abd. "Abstract 305: Combination analysis for the potential chemomodulatory effects of mansorin-A and its naphthoquinone derivative (mansonone-G) to 5-fluorouracil against liver cancer cells." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-305.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Fluorouracil – Analyse"

1

Chen, Chen, Peng Chen, Xia Liu, and Hua Li. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients with Retinal Detachment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2021. http://dx.doi.org/10.37766/inplasy2021.8.0117.

Full text
Abstract:
Review question / Objective: The aim of this meta-analysis is to evaluate the efficacy and safety of intraoperative infusion of combined 5-fluorouracil and low molecular weight heparin (LMWH) for the prevention of postoperative proliferative vitreoretinopathy in patients with retinal detachment. Condition being studied: Postoperative proliferative vitreoretinopathy (PVR) is the primary cause of failure of retinal reattachment surgery. 5-fluorouracil (5-FU) inhibits the proliferation of fibroblasts, and suppresses collagen contraction. On the other hand, heparin reduces fibrin exudation, and inhibits the adhesion and migration of retinal pigment epithelial cells. We conduct this comprehensive literature search and meta-analysis to address whether intraoperative infusion of combined 5-FU and LWMH improves the primary success rate of pars plana vitrectomy, as well as reduces postoperative PVR. Our study aims to provide clinical evidence for retinal surgeons concerning their choice of intraoperative medication.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Fluorouracil – Analyse' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography